A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.

Jonathan L Metts,Matteo Trucco,Daniel A Weiser,Patrick Thompson,Eric Sandler,Tiffany Smith, Jessica Crimella,Samer Sansil,Ram Thapa,Brooke L Fridley, Nicholas Llosa,Thomas Badgett,Richard Gorlick,Damon Reed,Jonathan Gill

Cancer medicine（2023）

引用 3|浏览26

暂无评分

摘要

The MTD of VIT with metformin was not determined due to premature study closure. We recommend an RP2D of Dose Level 4, 1666 mg/m /day. Radiographic responses were seen in multiple tumor types. Further evaluation for efficacy could be investigated in a Phase II trial.

查看译文

关键词

irinotecan,metformin,pediatric,phase I,temozolomide,vincristine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要